Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update
March 16, 2021 08:00 ET
|
Prelude Therapeutics, Inc.
– Dose Escalation Portion of Phase 1 Trial of PRT543 Complete; Additional Expansion Cohorts Set to Initiate Early in the Second Quarter – – Clinical Data Readouts Expected in 2H21 for Lead PRMT5...
Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor Conferences
March 03, 2021 07:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced...
Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 11, 2021 18:20 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the...
Prelude Therapeutics Announces Pricing of Upsized Public Offering
January 07, 2021 00:12 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision...
Prelude Therapeutics Announces Launch of Proposed Public Offering
January 04, 2021 16:16 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that...
Prelude Therapeutics Announces Third Quarter 2020 Financial Results
November 10, 2020 07:30 ET
|
Prelude Therapeutics, Inc.
- Completed Initial Public Offering of Common Stock, Raising Gross Proceeds of ~$181.9M - - Partial Response Confirmed in Glioblastoma Multiforme Patient in Phase 1 Trial of PRT811 - - Durable...
Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies
September 30, 2020 07:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the first patient has been...
Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
September 29, 2020 16:05 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its initial public...
Prelude Therapeutics Announces Pricing of Initial Public Offering
September 24, 2020 20:50 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its initial public...